(Q36150572)

12 August 2017

1 reference

title

Pharmacotherapy of erectile dysfunction: focus on cardiovascular safety (English)

1 reference

12 August 2017

0 references

1 reference

Thorsten Reffelmann

1

1 reference

12 August 2017

Robert A Kloner

series ordinal

2

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 May 2005

1 reference

Expert Opinion on Drug Safety

12 August 2017

published in

1 reference

12 August 2017

volume

4

1 reference

12 August 2017

issue

3

1 reference

12 August 2017

page(s)

531-540

1 reference

ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.531

Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.531

Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.531

Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.531

Comparison of reported and expected deaths in sildenafil (Viagra) users

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.531

Effects of sildenafil on myocardial infarct size, microvascular function, and acute ischemic left ventricular dilation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.531

Management of sexual dysfunction in patients with cardiovascular disease: recommendations of The Princeton Consensus Panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.531

Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.531

Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.531

Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.531

Nitric oxide activity is deficient in spasm arteries of patients with coronary spastic angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.531

Time course of the interaction between tadalafil and nitrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.531

Effects of sildenafil citrate (viagra) on blood pressure in normotensive and hypertensive men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.531

Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Sildenafil Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.531

Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.531

Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.531

Cyclic nucleotide phosphodiesterase type 5 activity limits blood flow to hypoperfused myocardium during exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.531

Sildenafil citrate (Viagra) does not exacerbate myocardial ischemia in canine models of coronary artery stenosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.531

The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.531

The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.531

Modulation of human platelet aggregation by the phosphodiesterase type 5 inhibitor sildenafil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.531

Cardiac electrophysiologic and hemodynamic effects of sildenafil, a PDE5 inhibitor, in anesthetized dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.531

Effects of sildenafil citrate (viagra) on cardiac repolarization and on autonomic control in subjects with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.531

Sympathetic activation by sildenafil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.531

Sildenafil inhibits hypoxia-induced pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.531

Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.531

Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.531

Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.531

Lung cGMP release subsequent to NO inhalation in pulmonary hypertension: responders versus nonresponders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.531

Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure: a double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.531

Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.531

Cardiovascular events in users of sildenafil: results from first phase of prescription event monitoring in England

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.531

Triggering myocardial infarction by sexual activity. Low absolute risk and prevention by regular physical exertion. Determinants of Myocardial Infarction Onset Study Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.531

Vardenafil (Levitra) for erectile dysfunction: a systematic review and meta-analysis of clinical trial reports.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.531

Update on clinical trials of tadalafil demonstrates no increased risk of cardiovascular adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.531

Cardiovascular safety of sublingual apomorphine in patients on stable doses of oral antihypertensive agents and nitrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.531

21 January 2018

Identifiers

DOI

10.1517/14740338.4.3.531

1 reference

12 August 2017

1 reference